辉瑞 肿瘤科 has recruited Desperate Housewives 和 West Wing star Kathryn Joosten to feature in a national education campaign titled Lung Cancer Profiles, which aims to reduce stigma 和 plug molecular testing of the disease.

The push comes as 辉瑞 deepens its investment in narrowly-targeted cancer treatments whose success will require broad adoption of genetic testing.

两次艾美奖得主乔斯滕’与肺癌的十年斗争 lungcancerprofiles.com以及其他几位肺癌幸存者的故事,都是老年妇女。现年71岁的Joosten于2001年首次被诊断出患有NSCLC。她在45年后戒烟,接受了手术切除了I期肿瘤,直到2009年医生发现III期肿瘤才显示出癌症的迹象。

通过测试,她得知自己的癌症是EGFR阴性和KRAS阳性,她说:“这帮助我的医生找到了适合我类型肺癌的正确试验。”作为该试验的一部分,乔斯滕一直服用一种研究药物,并报告说:“我最近的扫描显示,一些结节缩小了,有些结节了,而且什么也没有增长。”

她在现场说:“尽管要测试我的肿瘤需要坚持不懈,但这对我来说很重要,我很自豪地说我在自己的健康中发挥了积极作用。”

辉瑞’s Xalkori (crizotinib) won FDA approval in August for treatment of some patients with late-non-small cell lung cancer (NSCLC) who have a genetic mutation which can fuel the growth of cancerous cells. The agency simultaneously approved a test for the mutated gene, known as an abnormal anaplastic lymphoma kinase gene, from Abbott Molecular 诊断程序. Around one out of every seven NSCLC patients have the gene. 辉瑞 和 Qiagen are also working on a drug-companion diagnostic combo for 辉瑞’达科替尼用于非小细胞肺癌的研究药物。这些产品的罪魁祸首是KRAS基因突变。 

辉瑞 is collaborating with a host of lung cancer patient advocacy orgs on the effort, including the Bonnie J. Addario Lung Cancer Foundation, Lung Cancer Alliance, Lung Cancer Foundation of America, LUNGevity, the National Lung Cancer Partnership 和 Uniting Against Lung Cancer.